The 2022 Multidisciplinary Head and Neck Cancers Symposium will take place February 24-26 in Phoenix, Arizona. This two-and-a-half-day meeting for the entire head and neck cancer community provides the most up-to-date information on multidisciplinary therapies, clinical research, treatment strategies, supportive care, scientific breakthroughs and toxicity mitigation.
The meeting is co-sponsored by the American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the American Head & Neck Society (AHNS) and the Society for Immunotherapy of Cancer (SITC).
Embargo Policy and Access to Abstracts
All abstracts to be presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium are embargoed until 8:00 a.m. Mountain time, Thursday, February 24, 2022. The embargo policy applies to all abstracts regardless of whether information is obtained from another source.
Embargo violations by media professionals may result in suspension of credentials at the symposium as well as future meetings and may also impact the ability to receive advance media materials for future meetings. Embargo violations by abstract authors and/or sponsors may result in removal of the abstract from the scientific program. Abstract authors are responsible for notifying financial and other sponsors about this embargo policy.
Questions about the embargo policy may be directed to ASTRO’s media relations team.
The full text of the abstracts selected for oral and poster presentation will be available online at the start of the meeting. Abstracts also will be published in an issue of the International Journal of Radiation Oncology • Biology • Physics (www.redjournal.org).
Complimentary registration is available for professional journalists representing media organizations for the express purpose of gathering news and information to produce press coverage of the symposium. Press registration is open to representatives of print, broadcast and online media outlets, including health care trade media (collectively known as press), as well as public information officers from educational institutions, government agencies and nonprofit cancer research organizations presenting research at the symposium.
For more information on press registration, contact ASTRO's media relations team.
Applicants may be asked to provide media credentials, a letter of assignment and/or bylined articles. Exhibitors are not permitted to register as press unless they can provide proof of editorial assignment from an accredited news organization that meets the above criteria. Public relations, marketing and/or advertising representatives, financial analysts, book publishers and book authors, and individuals from communications, print or online promotion services are welcome to register as regular attendees, however, they are not permitted to register as press. ASTRO reserves the right to bar from this and future meetings any journalist who misuses press privileges to engage in activities other than journalistic pursuits.
For More Information
For media-related questions and interview requests, email ASTRO’s media relations team or call us at 703-286-1600.
For details about the meeting, visit the symposium website.
For the latest updates, follow ASTRO on social media.
For general information about radiation therapy, visit RTAnswers.org.